Member Info for Eureka01

Amers, Previously you gave broad hints that you had insider knowledge of events to come. "There are alternative funding options available, but these cannot be disclosed until after the General Meeting. If the resolutions are voted down, those options will be revealed."

When I challenged you on this after the resolutions had been voted down you responded, "Pls just wait a week or so. Thanks"

Well, that time period has come and gone and not a word so you now need to come clean and state whether you did indeed have inside knowledge or whether your comments were what many here believe them to to be ....mere speculation. Thanks.

Good Morning All. More backwardation this morning. On dummy trades 0.515p to buy, 0-52p to sell. Someone wants your shares!

Following my previous post on the matter, I've had a further response concerning the implementation guide for CYP2C19.

"The implementation guide is currently going through NHSE genomics unit governance process. We will publish the documents once approval is received."

I was told that as a result of my enquiry, NHS England were contacted to jog them a bit! Question...Has the company not been chasing this matter up??

The hope, I was told, is that publication will be this quarter but then we've been there before with expectations, so we shall see. I was told that there were pros and cons to both tests and that the results of both the lab test and the POC pilot test will be published together.

At least we know that the implementation guide has not been forgotten about!!

Not sure if a delay in declaration is acceptable, Jimi.

"A shareholder must notify the AIM company and the London Stock Exchange without delay when their holding moves across a 1% threshold, such as from 15% to 16%."

EC, stick to this share. If you want to pump AGL do it on their board.

Here some 5 million sells have gone through and the sp hasn't budged. I suspect a large buyer in the background... David Nugent?

Now buys coming in at 0.55p. Yes, at the moment I'd say they want your shares. 🙂

Did some dummy trades just now. 0.50p to buy, 0.50p to sell. Then NT to buy. Interesting.

Thanks busicat. This is what johnlayc..k had previously been told by a contact in NICE in August:

"I believe the implementation guidance for clopidogrel use being developed by the CERSI will still progress and publish as will an implementation guide/pilot information document. So we are hoping there will be a repository of tools for those who may wish to implement sooner. I still don't have a publication date but I am hoping for mid-late September. I am meeting with the NHSE team in mid September to update wording on the NICE website and hope at that point to have an update re publication of the CERSI guidance and implementation guide."

So as NICE have not been able to provide an update thus far, the delays continue.

A month ago I wrote to NICE for guidance on the long overdue publication of the implementation guide for Genedrive's CYP2C19 ID Kit. The pilot trial ended early May of this year yet still not a word. The response finally came back today: "The pilot was run by NHS England and we have no further information on timescales for the publication of implementation support tools and associated guidance."

National implementation of the CYP2C19 test was to be decided through a joint process between NHS England and the National Institute for Health and Care Excellence (NICE) with NICE providing the clinical guidance for the test's use. So surprising that they have no information on the implementation.

At least we know that we're not the only ones in the dark. 🙂

Top percentage gainer of the day:

1 GDR Genedrive Plc 0.555 38.75% 0.155

What major share holders? The only other notifiable one is Robert English who holds 3.13%.

Hmm, but not actually answering my question.🙂

Amers: " BH, at present there may be a few options on the table — ones I can’t go into in detail right now. However, all will become clear soon."

But previously, as I pointed out, you had said: ""There are alternative funding options available, but these cannot be disclosed until after the General Meeting. If the resolutions are voted down, those options will be revealed."

However, apparently not ready to be revealed yet. So let's be crystal clear, is this firm knowledge that you have or is this speculation?

Amers: "In my view, once both parties start moving forward, the share price is poised to take off — it's only a matter of time. We just need to hold our nerve a little longer. Funding will happen — one way or another ..."

You have been leading a campaign for the last few weeks to vote No to the resolutions on the basis that you knew of better options available:

Previously you have said: "There are alternative funding options available, but these cannot be disclosed until after the General Meeting. If the resolutions are voted down, those options will be revealed."

DN, said in a previous post : "It is not down to me to fund this company in return for a board seat, I have never asked or agreed to this."

So I would like to know, now that the resolutions have been voted down and as DN does not seem to want to fund the company, what exactly is this alternative funding that you are so sure about? I'm sure all shareholders here would be glad to hear about it.

MMs up to their old tricks. NT to buy in any quantity.

No idea what will happen tomorrow but at the moment it's NT to buy but can sell in large quantity. The MMs want your shares!

"Genedrive LON:GDR was 45% higher on the day, with an additional update on equity financing lending support. A significant investor has been pushing back against the recent fund raise but is refusing to engage with management. Whether today’s update increases the prospect of the funding proposal failing at the general meeting and/or an opportunistic takeover bid being made remains to be seen."

https://www.thearmchairtrader.com/aim-market-roundup/genedrive-petromatad-alienmetals/

Halifax Jimi. The result in this situation is that many buys have been put down as sells. There was a trade at 11.01, for instance, where 3.4 million shares traded at .244p and had been put down as a sell but could well be a buy.

Interesting situation at the moment. I tried out a couple of dummy trades and it was .2444p to buy and .245p to sell.

I had a look at the pronouncements of the last 3 years and the excessive optimism is clear to see. Yes, there is always the clause at the end about principal risks and uncertainties. but I, like most I suspect, have previously focused on the main statements.

Final results Nov 22

"We have commenced the process for FDA approval of AIHL" Three years later and the company has yet to commence the formal submission.

Interims Mar 2023

"New commercial distribution agreements for AIHL in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey." But where are the significant sales?

"We are confident in gaining commercial traction and securing significant revenues". Two years later annual income of only £1million.

"This recommendation is expected to act as a catalyst for wider NHS adoption and, further, with NICE's reputation it is expected that the endorsement will also be beneficial to the assays commercial prospects as we seek to penetrate international territories". Still waiting for significant sales abroad.

"The Company is in ongoing dialogue still with the FDA to ascertain the requirements, and consequently the funding estimate that would be required to conduct and manage the evidence generation and submission process". Still waiting for the submission.

"We are optimistic about our ability to succeed in the future, by creating value for our shareholders and by improving people's lives". Up to now it has been destruction of shareholder value!

Finals Nov 23

"We continue to make progress for FDA approval of our MT-RNR1 product". Very slow progress!

Interims Mar 24

"It has been encouraging to see how we have been able to generate Genedrive® MT-RNR1 kit sales both inside and outside the UK in such a short space of time." But very limited abroad.

"I have also been keen to ensure we have the right strategy for our business overall, leading to tighter controls over costs." Why no previous director pay cuts then?

"We continue to pursue all avenues to ensure we achieve specialist commissioning before the current timescale of April 2025" 5 months beyond that date and still waiting.

"Our equity funding plans are being advanced and the intention will be to raise sufficient funding to complete the clinical trials and regulatory approval process in the USA for the AIHL test whilst also providing sufficient funding to cover the Company's operating costs for an appropriate period of time." Since then we have had three fund raises and likely to have another.

Finals Nov 24

"We have a pipeline of opportunities that, if converted, would see a significant step up in revenues during calendar year 2025 and a reduction in the level of cash burn." Still only £1million coming in.

IMC Dec 2024

National commissioning for AIHL test by April? "We remain confident of that." Still waiting.